Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
N/A N=61 Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals
Obesity · Overweight
Primary: Adherence Score — 0.57; 0.54; 0.59 score on a scale
Phase 1 N=23 A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
N/A N=51 Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Anxiety · Healthy Volunteers
Primary: Difference in Learning Rate — 0.009; 0.0058 unitless
Phase 1 N=23 A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Phase 1 N=18 A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
Healthy
Primary: Maximum Serum Concentration(Cmax) for PF-06823859 — 307.4 micrograms/milliliter (ug/mL)
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 1 N=18 A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
N/A N=330 Daily Habits & Consumer Preferences Study
Obesity
Primary: Hyperpalatable Food Intake — 325.95; 262.51 kilocalories
Phase 1 N=12 A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Phase 1 N=12 A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.
Healthy
Primary: Mean Score of Sensory Attributes Based on Palatability Assessment Questionnaire at 1 Minute Post-dose on Day 1 — 80.3; 49.4; 54.0; 48.5 Units on a scale
N/A N=330 To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans
Hypovitaminosis D
Primary: Plasma PTH Level — 58.29; 60.73; 57.88; 54.05 pg/ml
Early Phase 1 N=144 Inflammation and Daily Life Study
Inflammation
Primary: Loneliness — 47.9; 46.9; 46.8; 44.6 score on a scale
N/A N=180 The BrainHealth Project - Pilot Study
Healthy
Primary: The BrainHealth Index — 54 score on a scale — p=<0.001
N/A N=558 Feasibility Trial of the iAMHealthy Intervention
Obesity; Rurality
Primary: Participant Recruitment Rate — 99; 5 Participants
Phase 1 N=12 A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition — 671.6; 145.1; 84.96 Nanogram per milliliter (ng/mL)
N/A N=37 Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
Phase 1 N=16 A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Etrasimod — 1620; 1529; 1538; 1391…
N/A N=20 Effect of Ultra Processed Versus Unprocessed Diets on Energy Intake
Healthy Diet
Primary: Ad Libitum Energy Intake — 2963; 2491 kcal per day
N/A N=63 Hair2Go Label Comprehension and Usability Study
Hair Removal
Primary: Percent of Participants Correctly Determining Eligibility for Use of the Device (Responders) — 94 percentage of participants
N/A N=159 Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
Cognition
Primary: Relationship Between Prefrontal Cortex Activation and Respiratory Sinus Arrhythmia — -0.064; 0.00375 Micro mol per second — p=0.008
N/A N=92 Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease
Alzheimer Disease
Primary: Change in Plasma Amyloid Beta (Aβ) Levels — -0.38; 0.02; 0.24; -0.08 Z-score — p=0.003
N/A N=21 Noninvasive Modulation of Motivational Brain Regions in Healthy Volunteers
Traumatic Brain Injury
Primary: dACC BOLD Signal (After Active rTMS Session) — -1.14; -1.27 Percentage of BOLD signal change
Phase 1 N=24 A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of PF-07081532 — 2236; 2121; 2230; 1536 nanogram per milliliter (ng/mL)
Phase 1 N=8 A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
Healthy Participants
Primary: Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling — 666.4; 745.5 Nanogram*hour per milliliter…
N/A N=344 The Healthy Weigh Study
Obesity
Primary: Mean Weight Change — -6.86; -6.86; -2.82; -0.66 pounds
N/A N=62 Heart Rate and Breathing Effects on Attention and Memory
Aging · Alzheimer Disease · Age-related Cognitive Decline
Primary: Change in Plasma Amyloid Beta (Aβ) Levels — 0.343; -0.371; 0.381; -0.332 Z-score — p=0.817
N/A N=60 Congenital Heart Disease Physical Activity Lifestyle Study
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 3.4 average minutes per day — p=0.24